Lymphangioleiomyomatosis (LAM) is a progressive lung disease that primarily affects young women. Genetic evidence suggests that LAM cells bearing TSC2 mutations migrate to the lungs, proliferate, and cause cystic remodeling. The female predominance indicates that estrogen plays a critical role in LAM pathogenesis, and we have proposed that estrogen promotes LAM cell metastasis by inhibition of anoikis. We report here that estrogen increased LAM patient-derived cells' resistance to anoikis in vitro, accompanied by decreased accumulation of the proapoptotic protein Bim, an activator of anoikis. The resistance to anoikis was reversed by the proteasome inhibitor, bortezomib. Treatment of LAM patient-derived cells with estrogen plus bortezomib promoted anoikis compared with estrogen alone. Depletion of Bim by siRNA in TSC2-deficient cells resulted in anoikis resistance. Treatment of mice with bortezomib reduced estrogen-promoted lung colonization of TSC2-deficient cells. Importantly, molecular depletion of Bim by siRNA in Tsc2-deficient cells increased lung colonization in a mouse model. Collectively, these data indicate that Bim plays a key role in estrogen-enhanced survival of LAM patient-derived cells under detached conditions that occur with dissemination. Thus, targeting Bim may be a plausible future treatment strategy in patients with LAM.
Introduction
Lymphangioleiomyomatosis (LAM) is a devastating disease affecting young women. The proposed pathogenesis of LAM holds that histologically benign-appearing smooth muscle cells arise from an unknown source and metastasize to the lungs, where they promote destructive cystic remodeling. About 30%-40% of women with tuberous sclerosis complex (TSC), a genetic disorder caused by TSC1 and TSC2 gene defects, have radiographic evidence of LAM (1, 2) . A Mayo Clinic study of a series of TSC patients reported that LAM was one of the leading causes of death in women with TSC (3) . LAM also occurs in a sporadic form (S-LAM) in women who do not have TSC. In those patients, somatic TSC2 mutations have been reported in lesional cells from the lung, kidney, and lymphatics, but not in normal tissues from those organs or in circulating myeloid cells (4) . Multiple preclinical studies demonstrated the effectiveness of rapamycin, an mTORC1 inhibitor, in animal models of TSC (5) , which led to rapid clinical translation, and demonstration that rapamycin has clinical benefit in patients with LAM (6) . In patients with end-stage LAM, lung transplantation is offered as a last resort, although recurrence of LAM has been reported in the donor allograft (7) .
Lymphangioleiomyomatosis (LAM) is a progressive lung disease that primarily affects young women. Genetic evidence suggests that LAM cells bearing TSC2 mutations migrate to the lungs, proliferate, and cause cystic remodeling. The female predominance indicates that estrogen plays a critical role in LAM pathogenesis, and we have proposed that estrogen promotes LAM cell metastasis by inhibition of anoikis. We report here that estrogen increased LAM patient-derived cells' resistance to anoikis in vitro, accompanied by decreased accumulation of the proapoptotic protein Bim, an activator of anoikis. The resistance to anoikis was reversed by the proteasome inhibitor, bortezomib. Treatment of LAM patient-derived cells with estrogen plus bortezomib promoted anoikis compared with estrogen alone. Depletion of Bim by siRNA in TSC2-deficient cells resulted in anoikis resistance. Treatment of mice with bortezomib reduced estrogen-promoted lung colonization of TSC2-deficient cells. Importantly, molecular depletion of Bim by siRNA in Tsc2deficient cells increased lung colonization in a mouse model. Collectively, these data indicate that Bim plays a key role in estrogen-enhanced survival of LAM patient-derived cells under detached conditions that occur with dissemination. Thus, targeting Bim may be a plausible future treatment strategy in patients with LAM.
The reasons that LAM exclusively affects women remain unclear. The remarkable female predominance of LAM suggests that female hormones, including estrogen, may contribute to disease pathogenesis. Both LAM cells and angiomyolipoma cells express estrogen receptor α, estrogen receptor β, and the progesterone receptor (8) . We have previously discovered that estrogen promotes the survival and lung colonization of intravenously injected Tsc2-deficient rat-uterine leiomyoma-derived ELT3 cells in our preclinical mouse model of LAM (9) . In a similar xenograft tumor model, estrogen strongly enhanced the pulmonary metastasis of ELT3 cells, associated with an increase in MEK1/2-Erk1/2 signaling in circulating tumor cells. Collectively, our data indicate that estrogen plays a key role in promoting the survival of disseminated TSC2-deficient LAM-derived cells during disease progression (9) , although the precise mechanisms involved have remained elusive.
LAM has been described as a destructive, low-grade metastasizing neoplasm (10) . Cells carrying TSC2 mutations have been identified in body fluids including blood, chylous effusions, and urine from women with LAM (11) . Tumor cells become metastatic by dissociation from primary sites, survival in the vascular system, and proliferation in distal organs. Cells normally undergo anoikis (anchorage-dependent programmed cell death) after losing contact with extracellular matrix or neighboring cells. As a neoplastic strategy, tumor cells acquire resistance to anoikis to allow survival after detachment from the primary site and dissemination via lymphatic or vascular channels. Tumor cells can acquire resistance to anoikis through genetic mutations that lead to inactivation of the death receptor pathway of caspase activation or overexpression of antiapoptotic proteins, including Bcl-2 family members that contain the Bcl-2 homology (BH) domain 3 (11) (12) (13) . The Bcl-2-interacting mediator of cell death (Bim), a BH3-only protein, is a critical activator of anoikis. In healthy cells, Bim is inactivated by its interaction with the cytoskeleton (14) (15) (16) (17) (18) . Upon activation by apoptotic stimuli, Bim is phosphorylated by Erk1/2. Phosphorylation of Bim also promotes rapid proteasome-mediated degradation that facilitates cell survival (19) (20) (21) .
In this study, we tested the hypothesis that Bim is a critical mediator of estrogen-supported survival of TSC2-deficient LAM patient-derived cells. We report here that estrogen decreases Bim accumulation and induces resistance of LAM patient-derived cells to anoikis. Furthermore, depletion of Bim by small interfering RNA (siRNA) prevents anoikis in LAM patient-derived cells. Bortezomib treatment restores susceptibility to anoikis in estrogen-treated LAM cells by preventing Bim degradation. In vivo, pharmacological suppression of proteasome activity using bortezomib increases Bim accumulation and reduces estrogen-promoted lung colonization of Tsc2-deficient cells, and molecular depletion of Bim by siRNA resulted in enhanced survival of Tsc2-deficient cells in a mouse model of LAM.
Results
Estrogen-promoted resistance of TSC2-deficient LAM patient-derived cells to anoikis is associated with Erk1/2 and Akt activation in vitro. Previously, we showed that estrogen (E 2 ) induced the survival of Tsc2-deficient Eker leiomyoma-derived (ELT3) cells in detachment conditions (9) . To determine the mechanism responsible for E 2 -enhanced resistance of ELT3 cells to anoikis, we analyzed the effects of E 2 and Bim on anoikis. E 2 treatment decreased the population of late apoptotic (annexin V + propidium iodide + [PI + ]) cells compared with that of untreated cells (35.2 ± 1.0 vs. 20.3 ± 0.7) in detachment conditions, as analyzed by flow cytometry ( Figure 1A) . Similarly, E 2 treatment decreased the population of late apoptotic (annexin V + PI + ) cells compared with untreated LAM patient-derived cells (621-101 cells) (22) (45.6 ± 0.1 vs. 4.2 ± 0.3) ( Figure 1A ), suggesting that TSC2-deficient cells were protected from anoikis by E 2 treatment in detachment conditions. E 2 treatment also decreased the level of Bim protein in detachment conditions by 40% and 60%, within 60 minutes and 120 minutes, respectively ( Figure 1B) , which was inversely correlated with Bim stability.
Mutation of TSC2 leads to hyperactivation of mTORC1 and dysregulation of PI3K-Akt via feedback inhibition mechanisms (23) . The expression of Bim is regulated both transcriptionally and posttranscriptionally by PI3K/Akt and Erk1/2 signaling networks (24) . We next assessed the effect of E 2 on the activation of these signaling molecules in TSC2-deficient cells grown in detachment conditions. E 2 treatment resulted in Erk1/2 phosphorylation within 5 minutes that continued up to 30 minutes after treatment, and Akt phosphorylation (Ser473) within 30 minutes that lasted up to 120 minutes after treatment in detached ELT3 cells ( Figure  1B) , indicating a correlation between E 2 -induced Bim downregulation and reactivation of Akt and Erk1/2 in Tsc2-deficient cells grown in detachment. To determine whether Bim expression is related to the biochemical features of TSC2-deficient cells, we compared the protein levels of Bim and S6 activation in detached ELT3 cells. E 2 treatment decreased the levels of Bim protein by 40% and 60%, at 60 minutes and 120 minutes, respectively. Interestingly, S6 phosphorylation was undetectable within the first 5 minutes, and gradually increased between 15 and 60 minutes of E 2 stimulation ( Figure 1B ), representing an inverse correlation between Tsc2 deficiency and Bim expression, in agreement with an earlier report that loss of Tsc2 leads to anoikis resistance and anchorage-independent growth (25) . TSC2-deficient cells exhibit hyperactivation of mTORC1, thus leading to constitutive phosphorylation of S6. We found that S6 phosphorylation was undetectable in Tsc2-deficient ELT3 cells grown in suspension ( Figure 1B ), indicative of detachment-induced suppression of mTORC1 signaling. Furthermore, E 2 treatment of 621-101 cells for 24 hours decreased the protein levels of Bim by 39% relative to control ( Figure 1C ), and correlated with the increased phosphorylation of Erk1/2 in detachment conditions. Importantly, decreased anoikis was associated with decreased levels of cleaved caspase 3 in E 2 -treated 621-101 cells compared with control cells ( Figure 1C ). Next, we examined the rapid effect of E 2 on Bim levels in detached 621-101 cells. E 2 treatment decreased the levels of Bim protein by 50% and 40% within 15 minutes and 30 minutes, respectively ( Figure 1D ). Importantly, the E 2 -promoted reduction of Bim was associated with Erk1/2 activation and PARP cleavage, suggesting that E 2 protects LAM patient-derived cells from detachment-promoted apoptosis.
Bim depletion promotes anoikis resistance of TSC2-deficient cells. To determine whether Bim is a key mediator of detachment-induced death in Tsc2-deficient ELT3 cells, we knocked down Bim using 2 independent
Figure 1. Estrogen decreases Bim expression in detached ELT3 cells and 621-101 cells. (A) Tsc2-deficient rat uterine leiomyoma-derived (ELT3) cells (upper panels) and TSC2-deficient LAM patient-derived cells (621-101 cells) (lower panels)
were seeded in poly-HEMA-coated plates, and treated with 10 nM 17-β-estradiol (E 2 ) for 24 hours. Cells were stained with a BD Annexin V: FITC Apoptosis Detection Kit I. Anoikis was determined by flow cytometry (BD FACSCanto II). Annexin V + PI + indicated cells undergoing anoikis (n = 3). (B) Immunoblotting analysis of Bim levels in ELT3 cells treated with E 2 for indicated periods. (C) 621-101 cells were treated with 10 nM E 2 or vehicle control for 24 hours in detachment conditions. Cleaved caspase 3 was used as an additional cell death marker. (D) 621-101 cells were treated with 10 nM E 2 for 5, 15, and 30 minutes in detachment conditions. Immunoblotting analyses of Bim, phospho-Erk1/2, Erk1/2, and cleaved PARP were performed. In B-D, β-actin was used as a loading control; Bim levels were quantified using densitometry, and normalized to β-actin. Results are representative of 3 experiments. Statistical analysis performed using an unpaired, 2-tailed Student's t test. **P < 0.01 was considered significant.
Bim siRNAs. We found that ELT3 cells transfected with these 2 rat Bim siRNAs exhibited 50% and 52% reduction of the transcript levels of Bim measured by real-time RT-PCR ( Figure 2A) , and 50% and 20% decrease of the protein levels of Bim, based on densitometry of immunoblots using an anti-Bim antibody, relative to control siRNA treatment ( Figure 2B ). Next, we compared the levels of cleaved caspase 3 as a marker of cell death. ELT3 cells were transfected with the 2 Bim siRNAs for 24 hours in adherent conditions, collected, and cultured in poly(2-hydroxyethyl methacrylate) (poly-HEMA)-coated plates for 24 hours, and then analyzed by immunoblotting. The results show that Bim siRNA-transfected ELT3 cells had lower levels of cleaved caspase 3 compared with cells transfected with control siRNA ( Figure  2B ), suggesting that Bim is a critical mediator of detachment-triggered death of ELT3 cells. Furthermore, we used flow cytometry to assess the effect of Bim depletion on the survival of ELT3 cells in detachment conditions. The percentage of ELT3 cells in late apoptosis (annexin V + PI + ) was decreased from 49% to 43%, or from 49% to 33%, after 2 independent Bim knockdowns ( Figure 2C ), further supporting Bim as a critical mediator of detachment-promoted death of Tsc2-deficient cells.
Next, we depleted Bim using 2 independent human Bim siRNAs in 621-101 cells. Forty-eight hours after siRNA transfection, the transcript levels of Bim were reduced by 41% and 38% ( Figure 2D ), and protein levels were decreased by 60% and 40%, relative to control siRNA treatment ( Figure  2E ). Levels of cleaved PARP and cleaved caspase 3 were markedly decreased in 621-101 cells transfected with the 2 Bim siRNAs compared with control siRNA treatment ( Figure 2E ). Moreover, the percentage of 621-101 cells in late apoptosis (annexin V + PI + ) was decreased from 52% to 20%, or from 52% to 24%, after 2 independent Bim knockdowns ( Figure 2F ). Collectively, our findings demonstrate that Bim is a critical regulator of detachment-induced apoptosis of TSC2-deficient cells.
Bim mediates E 2 -promoted cell survival and lung colonization of Tsc2-deficient ELT3 cells in vivo. To investigate the impact of Bim-mediated anoikis on tumor cell survival in a preclinical model of LAM, we intravenously injected female SCID mice with ELT3 luciferaseexpressing (ERL4) cells transfected with rat Bim siRNA (number 1) or control siRNA. At 6 hours after cell injection, Bim-depleted cells colonized the lungs more extensively than control siRNA-transfected cells, as indicated by bioluminescence intensity (Figure 3A ), although this difference was not statistically significant. Importantly, at 24 hours after cell injection, the control siRNA-transfected cells were barely detectable in the lungs of SCID mice, whereas the Bim-knockdown cells showed a strong and persistent bioluminescence signal. To determine the specificity of Bim depletion in lung colonization, we transfected ERL4 cells with a second Bim siRNA (number 2) or control siRNA, and then injected these cells intravenously into female SCID mice. At 6 hours after cell injection, all mice exhibited enhanced bioluminescence intensity. Importantly, at 24 hours after cell injection, the control siRNA-transfected cells were barely detectable in the lungs of SCID mice, whereas the Bim-knockdown cells showed markedly greater bioluminescence signal relative to the controls ( Figure 3B ). Quantification of the bioluminescence intensity in mouse lungs showed that ERL4 cells treated with the 2 independent Bim siRNAs exhibited a 5-fold and 6-fold increase in lung colonization relative to control siRNA treatments ( Figure 3C ). Collectively, these data further support the notion that Bim is a critical regulator of the survival of TSC2-deficient cells in vivo. E 2 activates Erk1/2 and increases anoikis resistance of ELT3 and LAM patient-derived cells via Bim degradation in vitro. We have found that Erk1/2 is highly activated by E 2 treatment in ELT3 cells and 621-101 cells in vitro ( Figure 1) and that E 2 treatment leads to increased lung colonization of ELT3-luciferase cells in vivo (7) . To investigate the molecular mechanisms of these effects, we examined signaling events underlying the reduced levels of Bim in E 2 -treated ELT3 cells and 621-101 cells. Flow cytometry analyses showed that E 2 
(C)
Immunoblotting analysis shows levels of phospho-Erk1/2, Erk1/2, Bim, and cell death markers cleaved caspase 3 and cleaved PARP in detached ELT3 cells treated with 10 nM E 2 with or without 50 μM PD98059, or 100 nM BTZ, or both PD98059 and BTZ. Bim levels were quantified using densitometry, and normalized to β-actin. The lanes were run on the same gel, but were noncontiguous. (D) 621-101 cells were seeded in poly-HEMA-coated plates, pretreated with or without 50 μM PD98059, a selective Erk1/2 inhibitor, or 100 nM BTZ, or both PD98059 and BTZ for 15 minutes. The treatments were continued for an additional 24 hours in the presence of E 2 (10 nM) or vehicle control. Cell death was analyzed by flow cytometry (n = 3). (E) The percentage of late apoptotic (annexin V + PI + ) cells was determined (n = 3). (F) Immunoblotting analysis shows levels of phospho-Erk1/2, Erk1/2, Bim and cell death markers cleaved caspase 3 and cleaved PARP in detached 621-101 cells treated with 10 nM E 2 with or without 50 μM PD98059, or 100 nM BTZ, or both PD98059 and BTZ. Bim levels were quantified using densitometry, and normalized to β-actin (obtained from replicate samples run in parallel). Results are representative of 3 experiments. Statistical analysis performed using a 1-way ANOVA test (Tukey's multiple comparisons test multiple pairwise comparisons between different groups). *P < 0.05, **P < 0.01, or ***P < 0.005 was considered significant. treatment decreased the population of detached cells in late apoptosis (annexin V + PI + ) by 40% ( Figure  4, A and B) . We also found that the E 2 -mediated decrease in the population of cells in apoptosis was partially attenuated by ~45% upon treatment with the Erk1/2 inhibitor PD98059 ( Figure 4, A and B) . Similarly, PD98059 treatment restored the protein levels of Bim in E 2 -treated ELT3 cells ( Figure 4C ). Importantly, cells treated with E 2 plus PD98059 exhibited higher levels of cleaved caspase 3 compared with E 2 treatment alone ( Figure 4C) . Similar findings were observed in detached 621-101 cells (Figure 4 , D-F). Together, these data support a role for Bim in mediating E 2 -protected anoikis via Erk1/2 in TSC2-deficient ELT3 and 621-101 cells.
Bortezomib restores Bim-mediated anoikis of ELT3 and LAM patient-derived cells in vitro. The results above indicate that E 2 -induced activation of the Erk1/2 pathway contributes to the survival advantage of ELT3 cells and 621-101 cells in detachment conditions. Since Bim is inactivated by proteasome-mediated degradation (26-28), we evaluated the effects of proteasome inhibition on Bim depletion and cell death signaling. We treated detached cells with bortezomib (BTZ) with concurrent E 2 stimulation. FACS analysis revealed that BTZ blocked the E 2 -enhanced survival of ELT3 cells in vitro. (Figure 4A ). The percentage of cells in late apoptosis (annexin V + PI + ) was increased markedly in cells treated with BTZ plus E 2 compared with that in cells treated with E 2 alone ( Figure 4B) . Similarly, BTZ treatment restored the protein levels of Bim in E 2 -treated ELT3 cells ( Figure 4C ). Importantly, cells treated with E 2 plus BTZ exhibited higher levels of cleaved caspase 3 and cleaved PARP compared with E 2 treatment alone ( Figure  4C) . Similar findings were observed in detached 621-101 cells (Figure 4 , D-F). Collectively, our data
Figure 5. The proteasome inhibitor bortezomib blocks lung colonization of ELT3 cells in vivo. (A)
Simplified study flow. Female ovariectomized SCID mice receiving vehicle control (n = 5) or estrogen (E 2 ) in drinking water were treated with bortezomib (BTZ; 1 mg/kg, dissolved in 100 μl PBS, i.p., n = 5) or control (sterilized PBS, n = 5) 24 hours in advance of cell injection and 6 hours after cell inoculation. Luciferase-expressing ELT3 (ERL4) cells were injected in female SCID mice intravenously; the baseline bioluminescence images were captured immediately, and 6 and 24 hours after cell injection. A second dose of BTZ or control was administered 6 hours after cell injection. (B) Bioluminescence imaging was performed at the indicated times. (C) Bioluminescence intensity (total photon flux) was recorded and quantified. Data are the mean bioluminescence intensities from 5 mice per group. Statistical analysis performed using a 1-way ANOVA test (Tukey's multiple comparisons test multiple pair-wise comparisons between different groups). *P < 0.05 or **P < 0.01 was considered significant. support that Bim mediates E 2 -promoted resistance to anoikis in part via proteasome activity that can be targeted by BTZ in TSC2-deficient ELT3 and 621-101 cells in vitro. Of note, BTZ treatment attenuated E 2 -protected anoikis to a greater extent in ELT3 (Figure 4 , A-C) than that in 621-101 cells ( Figure  4 , D-F), indicative of tissue specificity. Furthermore, we examined the effect of the combinatorial treatment of BTZ and PD98059 on the survival of ELT3 and 621-101 cells in the presence of E 2 in detachment conditions. ELT3 cells treated with E 2 plus BTZ and PD98059 exhibited higher levels of cleaved caspase 3 and cleaved PARP compared with E 2 treatment alone ( Figure 4C) . Similar findings were observed in detached 621-101 cells (Figure 4 , D-F), indicating that E 2 protects cells from anoikis via multiple mechanisms.
BTZ reverses E 2 -promoted lung colonization of ELT3-luciferase cells in vivo.
To further investigate the role of Bim in the survival of ELT3 cells in vivo, ERL4 cells cultured in detachment conditions were treated with 10 nM E 2 or vehicle control for 24 hours. Cells were resuspended at the same density and intravenously injected into mice pretreated with BTZ 1 day prior to cell inoculation. At the baseline, similar levels of bioluminescence were observed in the chest regions of all mice ( Figure 5A) . At 6 and 24 hours after cell injection, the bioluminescence in the chest regions of mice inoculated with BTZ-treated cells was decreased by 40% and 70%, respectively, compared with the controls (Figure 5, B and C) . These data suggest that Bim plays a critical role in lung colonization by Tsc2-deficient ELT3 cells, in part owing to BTZ's ability to preserve Bim.
Figure 6. Low Bim accumulation is evident in LAM nodules.
Immunofluorescence staining of Bim (green) and smooth muscle actin (SMA) (red) in 2 cases of (A) lung adenocarcinomas and 2 cases of (B) LAM lung tissues. Nuclei were stained with DAPI (blue). Scale bar: 50 μm.
The expression of Bim is low in LAM lung nodule cells. It has been reported that Bim is overexpressed in lung adenocarcinomas relative to normal alveolus (29) . We first validated the quality of Bim immunostaining using 2 cases of lung adenocarcinomas. As expected, Bim accumulation was distinct in nodular regions of both lung adenocarcinoma specimens compared with peripheral smooth muscle actin (SMA) immunoreactivity ( Figure 6A ). We then examined whether our in vitro and in vivo findings of Bim levels were relevant to human LAM. Immunofluorescence staining showed that SMA-positive LAM lesions express lower levels of Bim compared with adjacent lung parenchyma, whereas Bim accumulation is abundant in lung cells ( Figure 6B ).
Discussion
LAM is a predominantly female lung manifestation characterized by the accumulation of abnormal smooth muscle cells in the lung parenchyma and severe emphysema-like lung destruction that can lead to respiratory failure and mortality (10, (30) (31) (32) . The marked gender specificity of LAM suggests that circulating female hormones including estrogen promote disease progression. We previously reported that estrogen promoted the survival of tuberin-deficient cells (9) . In this study, we identified that Bim is a critical mediator of estrogen-enhanced survival in detachment conditions in LAM patient-derived cells. Importantly, targeting Bim turnover with proteasome inhibitors has a tumor suppression effect in animal models of LAM. Molecular and functional analyses of anoikis resistance of LAM patient-derived TSC2deficient cells may provide insights into the biology of LAM pathogenesis.
Adhesion to the appropriate extracellular matrix is necessary for normal stromal cells to survive and proliferate, and loss of this adhesion leads to anoikis. Anoikis prevents detached cells from reattaching to an inappropriate site and growing. Acquired resistance to anoikis allows tumor cells to survive and disseminate from the primary tumor site to form a distinct lesion at the distal site. Little is known about the molecular mechanisms underlying E 2 -induced survival and metastasis of tuberin-deficient cells. The impact of E 2 on the growth of tuberin-deficient cells has been reported (9, (33) (34) (35) (36) (37) (38) (39) (40) . Gu et al. reported that E 2 activates Erk1/2 and increases the migration and invasion of tuberin-deficient cells (41) . We hypothesize that E 2 activates MEK1/2-Erk1/2 pathways to inhibit the accumulation and turnover of the proapoptotic protein Bim, leading to anoikis resistance in tuberin-deficient cells.
In this study, the MEK1/2 inhibitor PD98059, or the proteasome inhibitor BTZ, had a moderate effect on attenuation of E 2 -enhanced protection from apoptosis in detached TSC2-deficient cells. We also found that PD98059 treatment had limited inhibition of Erk1/2 activation in ELT3 cells and 621-101 cells, although E 2 -protected anoikis was not drastically attenuated by PD98059 treatment, suggesting that E 2 functions through other mechanisms to suppress detachment-induced apoptotic machinery as reported by Frisch and Screaton (42) . Moreover, BTZ treatment attenuated E 2 -protected anoikis to a greater extent in ELT3 than that in 621-101 cells, indicative of tissue specificity (36, 43, 44) . Importantly, the combinatorial treatment of PD98059 and BTZ induced more drastic anoikis in E 2 -treated ELT3 and 621-101 cells, further supporting the notion that E 2 protects cells from anoikis via multiple mechanisms.
We previously found that E 2 enhances the survival and metastasis of tuberin-deficient cells. In this study, we reinforce the concept that Bim is a key mediator of E 2 -promoted survival and we identify the signaling events that underlie the enhanced levels of Bim in E 2 -treated ELT3 cells. As a key BH3 protein regulating anoikis, Bim is regulated both transcriptionally and posttranslationally by the PI3K/Akt and Erk1/2 signaling networks (22) . We provide evidence that a modest reduction in Bim expression can substantially increase the survival and metastasis of tuberin-deficient cells in vivo, and the proteasome inhibitor, BTZ, blocks the E 2 -induced survival of ELT3 cells in vivo (illustrated in Figure 7) .
Little is known about the molecular mechanisms underlying LAM pathogenesis. Cells carrying TSC2 mutations have been identified in body fluids including blood, chylous effusions, and urine from women with LAM (11) . We previously found that E 2 enhanced the survival of disseminated ELT3 tumor cells and promoted the lung metastasis of ELT3 cells, both of which are associated with E 2 -induced anoikis resistance (9) . LAM has been described as a destructive, low-grade metastasizing neoplasm (10) . It is well known that in cancer cells including colon and mammary tumors, anoikis is triggered by detachment from the extracellular matrix and determined by Bim upregulation. Collectively, these findings imply that anoikis resistance may be a common mechanism leading to disease progression for LAM and other malignancies. Our data indicate that Bim accumulation and proteasome activity are critical components facilitating E 2 -enhanced survival in detachment conditions in LAM patient-derived cells. Thus, targeting Bim-mediated survival pathways including the proteasome may be a plausible future treatment strategy in patients with LAM.
Methods
Cell culture and reagents. ELT3 cells (36, 45) were provided by C. Walker, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas, USA. ERL4 (9) and LAM patient-associated angiomyolipoma-derived cells (621-101 cells) were provided by E.P. Henske, Brigham and Women's Hospital-Harvard Medical School (9, 22) . Cells were cultured in DMEM/F12 supplemented with 10% FBS, 0.2 μM hydrocortisone, 0.1 nM triiodothyronine, 0.01 μU/ml vasopressin, 1.6 μM FeSO 4 , cholesterol, ITS, 100 ng/ml EGF, 100 μg/ml zeomycin, and 1% penicillin-streptomycin-amphotericin B. 17-β-estradiol (E 2 ) (10 nM, Sigma-Aldrich), PD98059 (50 μM, Cell Signaling Technology), and BTZ (100 nM, Velcade) were used as indicated.
Detached cell culture. Cells suspended in serum-free media were seeded onto 6-well plates (BD Falcon) coated with 1.2% poly-HEMA (Sigma-Aldrich, P3932-10G), and treated with indicated reagents. siRNA transfections. Two independent human Bim siRNAs (50 nM) (Dharmacon, LU-004383-00-0002 and L-004383-00-0005) were transfected into 621-101 cells, and 2 independent rat Bim-siRNAs (50 nM) (Dharmacon, LQ-093533-02-0002 and L-093533-02-0005) were transfected into ELT3 cells and ERL4 cells using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's protocols. Cells were harvested 48 hours after transfection.
Quantitative RT-PCR. RNA from cultured cells was isolated using an RNeasy Mini Kit (Qiagen). Gene expression was quantified using One-Step qRT-PCR Kits (Invitrogen) in the Applied Biosystems Step One Plus Real-Time PCR System, and normalized to β-actin (human) or α-tubulin (rat). Primers used for 621-101 cells and ELT3 cells were: human β-actin forward CACCATTGGCAATGAGCGGTTC and reverse AGGTCTTTGCGGATGTCCACGT; human Bim forward ATCGCCCTGTGGATGACTGAGT and reverse GCCAGGAGAAATCAAACAGAGGC; rat α-tubulin forward GACCTGGAACCCACAGTTATT and reverse ATCTTCCTTGCCTGTGATGAG; rat Bim forward ATGGCCAAGCAACCTTCTGA and reverse GCTCCTGTCTTGCGATTCTG.
Immunoblotting and antibodies. Cells were lysed in m-PER buffer (Pierce). All primary antibodies were diluted in 1× phosphate buffered saline (PBS) supplemented with 0.5% Tween 20 (PBST). Antibodies used were Bim/BOD (diluted 1:500; ENZO, catalog ADI-AAP-330-E); β-actin (diluted 1:5,000; Sigma-Aldrich, catalog A5441); and the following from Cell Signalling Technology: phospho-Akt (S473) (diluted 1:1,000; catalog 9271); Akt (diluted 1:1,000; catalog 9272); phospho-Erk1/2 (T202/Y204) (diluted 1:2,000; catalog 9101); Erk1/2 (diluted 1:2,000; catalog 9102); phospho-S6 ribosomal protein (Ser235/236) (diluted 1:2,000; catalog 2211); S6 ribosomal protein (diluted 1:2,000; catalog 2317); cleaved caspase 3 (diluted 1:500; catalog 9661); cleaved PARP (human) (diluted 1:500; catalog 9541); cleaved PARP (rat) (diluted 1:500; catalog 9545).
Immunofluorescence staining. Sections were deparaffinized, incubated with anti-Bim (1:100 in PBS + 3% BSA, ENZO, catalog ADI-AAP-330-E) and anti-SMA (1:200 in PBS + 3% BSA, Santa Cruz Biotechnology, catalog sc32251), and secondary antibodies (1:1,000; Invitrogen, catalog A-21202 and A10042). Images were captured with an Olympus BX60 fluorescence microscope.
Fluorescence-activated cell sorting. An Annexin V: FITC Apoptosis Detection Kit I (BD catalog 556547) was used to stain detached ELT3 cells and 621-101 cells according to the manufacturer's protocols. FACS analysis was carried out on a BD FACSCanto II.
Animal studies. Intact or ovariectomized female C.B_Igh-1b/IcrTac-Prkdcscid (SCID) mice at 4 to 6 weeks of age were purchased from Taconic Biosciences. E 2 was dissolved initially in 0.5 ml 95% ethanol (stock concentration, 1 mM), and solubilized E 2 was added to the drinking water to produce a concentration of 500 nM for oral administration as previously described (46) . The water intake was monitored and water bottles were changed twice per week. BTZ (1 mg/kg, dissolved in 100 μl 1× PBS) was administered intraperitoneally (47, 48) ; the first dose was given 1 day prior to cell inoculation, and the second dose at 6 hours after cell inoculation. Cells (2 × 10 5 ) were injected into mice intravenously as previously described (9) . Animal health was monitored daily during the tumor experiments. All mice were euthanized by carbon dioxide (CO 2 ) inhalation via compressed gas after the last image was taken.
Bioluminescent reporter imaging. Ten minutes prior to imaging, mice were given D-luciferin (120 mg/ kg, i.p., PerkinElmer Inc., catalog 122799). Bioluminescent signals were recorded using the Xenogen IVIS Spectrum System. Total photon flux of chest regions was analyzed as previously described (9) .
Statistics. Data represent the mean ± SEM. Statistical analyses were performed using a 2-tailed Student's t test when comparing 2 groups for in vitro and in vivo studies, and 1-way ANOVA test (Dunnett's multiple comparisons test when comparing multiple groups with control group, Tukey's multiple comparisons test when making multiple pair-wise comparisons between different groups) for multiple group comparison. A P value less than 0.05 was considered significant.
Study approval. The University of Cincinnati Standing Committees on Animals approved all procedures described according to standards as set forth in The Guide for the Care and Use of Laboratory Animals. The Institutional Review Board of the University of Cincinnati approved all relevant human studies.
